Silver Book Fact

Pioglitazone associated with relative risk reduction in recurrent stroke

The PROactive trial to manage glucose in diabetics with a history of cardiovascular disease, stroke, or other vascular risk factors found that treatment with pioglitazone was associated with a 47% relative risk reduction in recurrent stroke.

Wilcox, Robert, Marie-Germaine Bousser, John Betteridge, Guntram Schernthaner, Valdis Pirags, Stuart Kupfer, and John Dormandy; for the PROactive Investigators. Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04). Stroke. 2007; 38(3): 865-73. http://stroke.ahajournals.org/cgi/content/short/38/3/865

Reference

Title
Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04)
Publication
Stroke
Publication Date
2007
Authors
Wilcox, Robert, Marie-Germaine Bousser, John Betteridge, Guntram Schernthaner, Valdis Pirags, Stuart Kupfer, and John Dormandy; for the PROactive Investigators
Volume & Issue
Volume 38, Issue 3
Pages
865-73
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The greater use of medications and revascularization would provide approximately a 17% reduction in 2 year mortality combined.  
  • Increased use of non-acute medications in primary and secondary prevention explains about 1/3 of the total reduction in cardiovascular disease mortality since 1950.  
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • Statin treatment soon after an acute heart attack reduces the risk of fatal heart disease or a recurrent heart attack by 24%.  
  • Life expectancy and quality of life gains from AVR
    A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years…